COST-UTILITY IN PRACTICE - A POLICY MAKERS GUIDE TO THE STATE-OF-THE-ART

被引:99
作者
GERARD, K [1 ]
机构
[1] UNIV ABERDEEN,HLTH ECON RES UNIT,ABERDEEN AB9 1FX,SCOTLAND
关键词
REVIEW OF COST-UTILITY ANALYSIS; COST-UTILITY ANALYSIS; ECONOMIC EVALUATION; QALY; COST PER QALY LEAGUE TABLES; PRIORITY SETTING; RESOURCE ALLOCATION;
D O I
10.1016/0168-8510(92)90022-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In recent years QALYs (quality adjusted life years) have achieved considerable fame or perhaps even notoriety in health services policy making. Yet little has been done to date to assess the potential benefit in policy terms of studies that have used cost-utility analysis (CUA). It was in recognition of this fact that this particular investigation was undertaken. An evaluation of 51 cost-utility studies is reported in the paper. Several criteria were applied to each study including aspects of technical and policy relevance. The main findings were: few studies had been undertaken; they were limited to few areas of health care; their technical execution was often of poor quality; the majority of studies used the empirical findings of health state valuations obtained from original developers of different quality of life techniques; and many claimed their results to be `favourable' (i.e. efficient interventions). This claim, however, is misguided because individual results get fed into generalised QALY league tables which ignore the context of specific studies and use results not performed on a common basis. Consequently, the state of the applied art of CUA is currently open to considerable question.
引用
收藏
页码:249 / 279
页数:31
相关论文
共 78 条
  • [51] UTILITY OF DIFFERENT HEALTH STATES AS PERCEIVED BY GENERAL PUBLIC
    SACKETT, DL
    TORRANCE, GW
    [J]. JOURNAL OF CHRONIC DISEASES, 1978, 31 (11): : 697 - 704
  • [52] ELECTIVE HYSTERECTOMY - BENEFITS, RISKS, AND COSTS
    SANDBERG, SI
    BARNES, BA
    WEINSTEIN, MC
    BRAUN, P
    [J]. MEDICAL CARE, 1985, 23 (09) : 1067 - 1085
  • [53] ECONOMIC-ANALYSIS OF AN IMMUNOSUPPRESSIVE STRATEGY IN RENAL-TRANSPLANTATION
    SCHNEIDER, T
    FAGNANI, F
    LANOE, JL
    HOURMANT, M
    SOULILLOU, JP
    [J]. HEALTH POLICY, 1988, 9 (01) : 75 - 89
  • [54] COMPARING THE COST-EFFECTIVENESS OF DRUG REGIMENS IN THE TREATMENT OF DUODENAL-ULCERS
    SINTONEN, H
    ALANDER, V
    [J]. JOURNAL OF HEALTH ECONOMICS, 1990, 9 (01) : 85 - 101
  • [55] COST-EFFECTIVENESS OF VACCINATION AGAINST PNEUMOCOCCAL PNEUMONIA - AN UPDATE
    SISK, JE
    RIEGELMAN, RK
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) : 79 - 86
  • [56] SMITH WGJ, 1989, EVALUATION RENAL SER
  • [57] PREVENTIVE THERAPY WITH ISONIAZID - COST-EFFECTIVENESS OF DIFFERENT DURATIONS OF THERAPY
    SNIDER, DE
    CARAS, GJ
    KOPLAN, JP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 255 (12): : 1579 - 1583
  • [58] *STAND MED ADV COM, 1990, BLOOD CHOL TEST COST
  • [59] STASON WB, 1988, DRUG INFORMATION J, V22, P539
  • [60] STENGELE U, 1991, J LITHOTR STONE DIS, V3, P133